These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Recent advances in heat shock protein-based cancer vaccines. Wang HH, Mao CY, Teng LS, Cao J. Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):22-7. PubMed ID: 16481277 [Abstract] [Full Text] [Related]
9. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Aalamian M, Fuchs E, Gupta R, Levey DL. Urol Oncol; 2006 Feb; 24(5):425-33. PubMed ID: 16962495 [Abstract] [Full Text] [Related]
10. Hsp receptors: the cases of identity and mistaken identity. Binder RJ. Curr Opin Mol Ther; 2009 Feb; 11(1):62-71. PubMed ID: 19169961 [Abstract] [Full Text] [Related]
11. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Hoos A, Levey DL. Expert Rev Vaccines; 2003 Jun; 2(3):369-79. PubMed ID: 12903802 [Abstract] [Full Text] [Related]
12. Heat shock protein-based cancer vaccines. Oki Y, Younes A. Expert Rev Vaccines; 2004 Aug; 3(4):403-11. PubMed ID: 15270645 [Abstract] [Full Text] [Related]
13. Adjuvants for vaccines, a quest. Audibert F. Int Immunopharmacol; 2003 Aug; 3(8):1187-93. PubMed ID: 12860174 [Abstract] [Full Text] [Related]
14. Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Murshid A, Gong J, Calderwood SK. Expert Rev Vaccines; 2008 Sep; 7(7):1019-30. PubMed ID: 18767951 [Abstract] [Full Text] [Related]
15. Heat shock proteins: applications in health and disease. Jindal S. Trends Biotechnol; 1996 Jan; 14(1):17-20. PubMed ID: 8579818 [Abstract] [Full Text] [Related]
16. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Bracci L, La Sorsa V, Belardelli F, Proietti E. Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607 [Abstract] [Full Text] [Related]
17. Current ideas about applications of heat shock proteins in vaccine design and immunotherapy. Wang XY, Li Y, Yang G, Subjeck JR. Int J Hyperthermia; 2005 Dec; 21(8):717-22. PubMed ID: 16338854 [Abstract] [Full Text] [Related]
18. Heat-shock proteins as drugs: potential applications in cancer, infections, and autoimmune and atopic diseases. Holzer AM, Martiniuk F, Levis WR. J Drugs Dermatol; 2007 Apr; 6(4):393-9. PubMed ID: 17668536 [Abstract] [Full Text] [Related]
19. Heat shock proteins gp96 as immunogens in cancer patients. Parmiani G, De Filippo A, Pilla L, Castelli C, Rivoltini L. Int J Hyperthermia; 2006 May; 22(3):223-7. PubMed ID: 16754342 [Abstract] [Full Text] [Related]
20. Soluble low-molecular-mass heat shock proteins and tumor-associated antigens in prevention and therapy of chemically-induced cancers. Zusman I, Kossoy G, Ben-Hur H. In Vivo; 2001 May; 15(6):529-34. PubMed ID: 11887340 [Abstract] [Full Text] [Related] Page: [Next] [New Search]